ADC (Antibody-Drug Conjugate) Series– category –
-
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Part 1 – Why is There an ADC Land Grab Now? Introducing ADC’s Place in Cancer Therapy
Over the past few years, headlines about Antibody-Drug Conjugates (ADCs) have become hard to miss in oncology and biopharma news. Over the past few years, headlines about Antibody-Drug Conjugates (ADCs) have become hard to miss in oncolo... -
Claudin18.2 ADC Development Part 4: Global Development Landscape and Future Outlook
Claudin18.2 (CLDN18.2)-directed ADCs are rapidly emerging as a cornerstone in the treatment of advanced gastric and gastroesophageal junction (GEJ) ca Claudin18.2 (CLDN18.2)-directed ADCs are rapidly emerging as a cornerstone in the trea... -
Claudin18.2 ADC Development Part 3: Comparative Analysis of SHR-A1904 and IBI343
Two phase 1 trials—SHR-A1904 and IBI343—have propelled the clinical development of CLDN18.2-directed ADCs. This article provides a head-to-head compar Two phase 1 trials—SHR-A1904 and IBI343—have propelled the clinical development of CLD... -
Claudin18.2 ADC Development Part 2: Phase 1 Results and Clinical Features of IBI343
In this article, we summarize the phase 1 trial of IBI343, reported in Nature Medicine (July 2025), focusing on its structural innovations, safety, efficacy, and position within the landscape of Claudin18.2-targeted ADCs. Drug Profile: M... -
Claudin18.2 ADC Development Part 1: Phase 1 Results and Clinical Significance of SHR-A1904
Antibody–drug conjugates (ADCs) targeting Claudin18.2 (CLDN18.2) have gained increasing attention as a novel therapeutic approach for advanced gastric and gastroesophageal junction (GEJ) cancers. Here, we summarize the phase 1 trial resu... -
Claudin18.2 ADC Development Part 0: Series Introduction
This series provides an in-depth review of the current landscape of Claudin18.2 (CLDN18.2)-targeted antibody–drug conjugates (ADCs) in gastric and gastroesophageal junction (GEJ) cancers. Structured into five parts, it covers pivotal cli... -
ADC Series – Bonus Chapter: Breakthroughs and the Fierce Global Race for Next-Generation Antibody-Drug Conjugates
Over the past few years, the landscape of Antibody-Drug Conjugates (ADCs) has undergone a dramatic transformation, shifting from a niche therapeutic approach to a central pillar of oncology innovation. Over the past few years, the landsc...
1